Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy als...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Alessandro Gozzetti, Francesca Bacchiarri, Vincenzo Sammartano, Marzia Defina, Anna Sicuranza, Bianca Mecacci, Elisabetta Zappone, Emanuele Cencini, Alberto Fabbri, Donatella Raspadori, Monica Bocchia
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2020-12-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	Daratumumab multiple myeloma rapid infusion safety efficacy
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2020.570187/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!